ProUroCare Medical Inc. · OTC:PUMD

ProUroCare Medical — Shareholder Meeting (August 2008)

14 slides from ProUroCare Medical's shareholder meeting presentation, Aug 12, 2008

  1. Slide 1: 2008 Annual Shareholders' Meeting

    1 2008 Annual Shareholders’ Meeting • Exhibit 99.1

  2. Slide 2: Safe-Harbor Statement

    2 Safe-Harbor Statement Certain statements contained in this presentation are forward-looking in nature, and are based on the current beliefs of our management as well as assumptions made by and information currently available to management, including statements related to the markets for our produc

  3. Slide 3: FORTUNE

    FORTUNE

  4. Slide 4: Prostate Cancer

    4 Prostate Cancer Second leading cause of death in men over 50 Three unique characteristics: Slowest growing cancer in men Prostate capsule containment Complications of treatment after age of 65 Government grant funding (NIH)

  5. Slide 5: Cancer Detection Tools

    5 Cancer Detection Tools DRE – Digital Rectal Exam PSA – Prostate Specific Antigen (blood test) Deficiencies of existing tools: Poor predictability DRE subjective and operator dependent PSA is derived result No physical record

  6. Slide 6: Market Value Proposition

    6 Market Value Proposition ProUroCare Our solution: Complementary tool Real-time imaging Physical base-line map Ongoing active surveillance

  7. Slide 7: ProUroScan System

    7 ProUroScan ProUroScan System System consists of rectal probe with a pressure sensor and position tracking system

  8. Slide 8: ProUroScan Output

    8 ProUroCare ProUroScan Output Software creates a multi-dimensional map of the prostate anatomy Measures stress patterns (elasticity) of prostate gland tissue Creates a map of prostate features and properties of the gland Base line measurement Ongoing surveillance

  9. Slide 9: Revenue Opportunities

    9 Revenue Opportunities Expected revenue sources: “Razors” and “Blades” Placement of the system ($25,000 $5,000) Sale of the test output ($120 – $150) Protective sheath ($2 - $3) Patient pay model CPT code and reimbursement fee ProUroCare

  10. Slide 10: Unique Market Opportunity

    10 Large, focused market 1 million biopsies per year (230k cancer diagnoses annually potential 2 million tests per year ) Potential BPH benchmark tool (50% at age 50) Innovative and patented technology Recognized standards of care (DRE/PSA) Documented unmet market need (DRE/PSA) Large number of moti

  11. Slide 11: Making It Happen

    11 R&D Partner (Artann) Contract Manufacturing Partner In discussions Sales & Marketing Partner Evaluating proposals Completed Making It Happen ProUroCare

  12. Slide 12: The Roadmap Forward

    12 The Roadmap Forward Systems being optimized for clinical testing More than 160 patients evaluated at Robert Wood Johnson Medical Center (Trenton, NJ) Test results correlate with clinical findings Recommended by NIH reviewers for Phase II grant Established agreements with Artann Labs Acquired crit

  13. Slide 13: Government Interest and Support

    13 Government Interest and Support Senators back $650 million bill for prostate cancer efforts. Barbara Boxer (D-Calif.) introduced the PRIME (Prostate Research, Imaging, and Men's Education) Act late last month, which she and Sens. Frank Lautenberg (D-N.J.) and prostate cancer survivor John Kerry (

  14. Slide 14: Thank You!

    FR ProUroCare ——— 14 Thank You!

ProUroCare Medical — Shareholder Meeting (August 2008) on 6ix